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Abstract
Prenatal hyperandrogenism is able to induce polycystic ovary syndrome (PCOS) in rats. The aim of the present study was to
establish if the levels of prenatal testosterone may determine the extent of metabolic and endocrine alterations during the
adult life. Pregnant Sprague Dawley rats were prenatally injected with either 2 or 5 mg free testosterone (groups T2 and T5
respectively) from day 16 to day 19 day of gestation. Female offspring from T2 and T5 displayed different phenotype of
PCOS during adult life. Offspring from T2 showed hyperandrogenism, ovarian cysts and ovulatory cycles whereas those from
T5 displayed hyperandrogenism, ovarian cysts and anovulatory cycles. Both group showed increased circulating glucose
levels after the intraperitoneal glucose tolerance test (IPGTT; an evaluation of insulin resistance). IPGTT was higher in T5 rats
and directly correlated with body weight at prepubertal age. However, the decrease in the body weight at prepubertal age
was compensated during adult life. Although both groups showed enhanced ovarian steroidogenesis, it appears that the
molecular mechanisms involved were different. The higher dose of testosterone enhanced the expression of both the
protein that regulates cholesterol availability (the steroidogenic acute regulatory protein (StAR)) and the protein expression
of the transcriptional factor: peroxisome proliferator-activated receptor gamma (PPAR gamma). Prenatal hyperandrogeniza-
tion induced an anti-oxidant response that prevented a possible pro-oxidant status. The higher dose of testosterone
induced a pro-inflammatory state in ovarian tissue mediated by increased levels of prostaglandin E (PG) and the protein
expression of cyclooxygenase 2 (COX2, the limiting enzyme of PGs synthesis). In summary, our data show that the levels of
testosterone prenatally injected modulate the uterine environment and that this, in turn, would be responsible for the
endocrine and metabolic abnormalities and the phenotype of PCOS during the adult life.
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Introduction
Polycystic ovary syndrome (PCOS), one of the most common
reproductive disorders, affects between 8 to 12% women in their
reproductive ages [1]. Women with PCOS display oligo or
anovulation, hyperandrogenism and/or ovarian cysts [2]. PCOS is
frequently associated with hyperinsulinaemia, insulin resistance
syndrome, increased cardiovascular risk and type 2 diabetes
mellitus [3–5]. Its etiology remains uncertain, but current theories
emphasize genetic and intrauterine origins coupled with environ-
mental factors such as diet and altered lifestyle patterns [3].
A battery of animal models used for the study of PCOS has
allowed focusing on different aspects of the pathology. In that
context, prenatal androgen exposure is able to induce PCOS and
metabolic syndrome in adult female rats [6–8], monkeys [9] and
sheep [10–12]. In the brain, a prenatal excess of testosterone
induces sex differences [9] and defeminization by increasing pulses
of gonadotropin-releasing hormone (GnRH) [13]. In addition, a
prenatal excess of testosterone increases body weight, induces
insulin resistance [8] and deficiency of 21-hydroxylase [14] during
the adult life. Recently, Legro et al [15] reported a direct
association between birth weight and metabolic phenotypes in
women with PCOS. However, data concerning the mechanisms
involved in the prenatal excess of androgen and change in the
secretion of hormones is still controversial [8,13,16].
Although it is well accepted that prenatally androgenized
animal models help in investigating the etiology of PCOS, little is
known about whether the androgen concentration of androgen
determines the phenotype of PCOS during the adult life. Then,
the aim of the present study was to determine whether different
doses of testosterone at fetal life have different life-long effects.
Prostaglandins (PGs) modulate different ovarian functions, such
as the rupture of ovarian follicles associated with ovulation [17,18]
and luteolysis [19,20]. In addition, PGE is increased in patients
with PCOS [21]. We have previously reported that hyperandro-
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tory status mediated by the PG system in mice [22,23]. For these
reasons we were interested in studying whether different levels of
prenatal exposure of testosterone induced a pro-inflammatory
status mediated by the PG system in ovarian tissue from adult rats.
The excess of androgen induces an imbalance in the ovarian
oxidant–antioxidant status characterized by increased production
of reactive oxygen species (ROS) [22–26]. It has been found that
one of the consequences of the increased generation of ROS
within ovarian cells is the loss of ovarian function including
steroidogenesis [19,20,23,27]. These findings led us to study
whether different levels of prenatal excess of testosterone induce
ovarian oxidative stress during the adult life.
The nuclear peroxisome proliferator-activated receptor (PPAR)
is a family of transcriptional nuclear factors with three isoforms
that regulates gene expression [28,29]. The three PPAR isotypes
(alpha, beta and gamma) are detected in developing follicles of
several species [29–35]. The activation of PPAR gamma regulates
the synthesis of steroid hormones in the granulosa cells [36], and
the disruption of PPAR gamma in the ovary leads to female
subfertility [37]. We have previously reported that acute hyper-
androgenization alters the expression of PPAR gamma during
early folliculogenesis in rats [38]. For these reasons, here we
studied if prenatal hyperandrogenism was able to alter ovarian
steroidogenesis through modulating the expression of PPAR
gamma. In summary, we studied whether prenatal hyperandro-
genism altered endocrine and metabolic pathways during the adult
life. We were also interested in establishing if the dose of
testosterone to which the fetus was exposed could determine the
phenotype of PCOS during the adult life.
Materials and Methods
Animals and treatments
Female rats of the Sprague Dawley strain were housed in group
cages under controlled conditions of light (12 h light, 12 h dark)
and temperature (23–25uC). Animals received food and water ad
libitum. Virgin female rats were mated with fertile males of the
Figure 1. Prenatal hyperandrogenization and body weight. Pregnant Sprague Dawley rats were subcutaneous injected with 2 or 5 mg free
testosterone from 16 to 19 day of pregnancy. Female offspring prenatally injected with 2 mg testosterone (T2 group), 5 mg testosterone (T5) or
vehicle (C). Panel (A) represents the weight at 21 days of age and panel (B) represents the weight at 60 days of age. Panel (C) represents the growth
rates of three groups control, T2 and T5; a vs b P,0.01; b vs c P,0.0001; a vs c P,0.001 by ANOVA test.Each column represents the mean+SEM from
ten different animals, N=20 animals/group.
doi:10.1371/journal.pone.0037658.g001
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which spermatozoa were observed in the vaginal fluid. Between
day 16 to day 19 of pregnancy, rats were hyperandrogenized as
described before [8]. Briefly, pregnant rats (N=120) received
subcutaneous injections of either 2 mg or 5 mg of free testosterone
(T-1500; Sigma, St. Louis, MO) dissolved in 100 ml sesame oil
from day 16 to day 19 of pregnancy whereas the control group
received only 100 ml of sesame oil. The doses of T2 of free
testosterone used result in circulating testosterone levels that are
similar to male rats [8,39]. Under the conditions of our animal
facilities, spontaneous term labor occurs on day 22 of gestation.
The treatments described did not modify the spontaneous term
labor, the female-to-male offspring ratio or the number of pups per
litter. Pups were culled from litters to equalize group sizes (ten
pups/each mother). Females were separated from males at 21 days
of age and randomly chosen. Animals were allowed free access to
Purina rat chow and water. All procedures involving animals were
conducted in accordance with the Animal Care and Use
Committee of Consejo Nacional de Investigaciones Cientı ´ficas y
Te ´cnicas (CONICET) 1996. The Ethic Committee of Facultad de
Medicina (UBA) approved the present study. The group of female
offspring prenatally treated with 2 mg testosterone was designated
as T2, whereas that corresponding to those prenatally treated with
5 mg was designed as group T5 and that without treatment as
control group.
Study protocols
To examine whether prenatal hyperandrogenization altered the
intra-uterine development, offspring from animals of the three
groups were weighed at 21 and 60 days of age. The offspring were
not weight at birth because at that time it was almost impossible to
determine reliably the sex of the rats. In addition, the weight at
birth has a significant higher error than at 21 days and
methodologically it is difficult since manipulation of the offspring
could conduce to the rejection of the mother. To establish if
prenatal hyperandrogenization induced defeminization, the uro-
genital distance was determined at 60 days of age. In order to
study whether treatments altered the estrous cycle, the estrous
cycle was determined by vaginal smears taken daily from 45 to 60
days of age (day of sacrifice). At 60 days of age, sixty female
Sprague Dawley rats per group of treatment were anesthetized
with carbon dioxide and killed by decapitation. Trunk blood was
collected and serum was separated by centrifugation at 1000 g for
15 min and stored at 280uC until estradiol, progesterone and
testosterone were determined by radioimmunoassay (RIA). Ova-
ries were immediately removed from each group (control, T2 and
T5) and divided as follows: 10 were immediately fixed in 4% (w/v)
paraformaldehyde for histological studies whereas 40 were
immediately frozen at 280uC. Then, 10 of the latter were used
for PGE determination by RIA whereas the other 30 used to
determine the ovarian oxidant-antioxidant balance (10 ovaries
were used to determine the lipid peroxidation index, 10 to
determine the nitric oxide synthase activity and 10 ovaries to
determine the total glutathione). Other 10 ovaries per group were
immediately homogenized in western blotting buffer and stored at
220uC until protein expression of cyclooxygenase 2 (COX2), the
limiting enzyme of PGs synthesis, steroidogenic acute regulatory
protein (StAR) and PPAR gamma.
Intraperitoneal glucose tolerance test (IPGTT)
As a measurement of glucose homeostasis and insulin resistance,
the intraperitoneal glucose tolerance test (IPGTT) was performed
in separate groups of ten animals per group (control, T2 and T5)
at 60 days of age after 8 h fast [8]. Briefly, a baseline blood sample
was obtained followed by intraperitoneal injection of 2 g/kg body
weight dextrose with blood sampling at 30, 60, 90 and 120 min.
Fasting blood glucose was determined by using the Haemoglu-
kotest (Roche) test strips for visual determination in the range of
20–800 mg/100 ml (1–44 mmol/l). The test principle uses the
glucose-oxidase/peroxidase reaction. Results are expressed in mg
glucose/dl.
Morphological studies
To study the effect of prenatal hyperandrogenization on the
ovarian function, ten ovaries from each group were fixed as
described above, were embedded in paraffin wax and consecu-
tively cut. To prevent counting the same follicle twice, 4-mm step
sections were mounted at 50-mm intervals onto microscope slides
according to the method described by Woodruff et al. [40]. To
count the number of different stages of follicles per ovary section, a
set of slides was stained with hematoxylin and eosin. An atretic
follicle was defined as the follicle that presented more than 10
pycnotic nuclei per follicle; in the smallest follicles, the criterion for
atresia was a degenerate oocyte, precocious antrum formation, or
both [41,42]. For morphological analysis, the sections were chosen
as follows: five from each extreme and five from the middle of each
ovary. Five ovaries from each group were observed for three
different researchers.
Progesterone and estradiol radioimmunoassay (RIA)
Serum progesterone and estradiol levels were determined by
specific RIA as described before [19]. Briefly, serum samples from
ten rats per treatment were extracted with the same volume of
diethyl ether three times. The extracts were collected and
evaporated in a vacuum oven and saved at 280uC until the
RIA was performed. The antibodies from progesterone and
estradiol were provided by Dr Niswender (Colorado State
University, Fort Collins, CO, USA). Both sensitivities were 5–
10 pg/tube, 2–5 ml of serum. Results are expressed as ng
progesterone or estradiol/ml serum.
Figure 2. Prenatal hyperandrogenization and glucose homeo-
stasis. As a measurement of glucose homeostasis, dynamic studies
were performed in female offspring of Sprague Dawley rats prenatally
injected with 2 mg testosterone (T2 group), 5 mg testosterone (T5) or
vehicle (C). Blood sample followed by itraperitoneal injection of 2 g
dextrose/kg body weight was collected at 0, 30, 60, 90 and 120 post-
injection. Each column represents the mean+SEM from ten different
animals, N=20 animals/group.
doi:10.1371/journal.pone.0037658.g002
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Testosterone was quantified by RIA as previously described
[43,44]. Briefly, serum samples were extracted as described for
progesterone and estradiol. The utility range of the assay was 25–
1600 pg. The intra-assay and inter-assay variations were 7.5 and
15.1%, respectively. Results are expressed as pg testosterone/ml
serum.
Prostaglandin radioimmunoassay (RIA)
To study whether prenatal hyperandrogenism was able to
induce a pro-inflamatory state in ovarian tissue, PGE was
determined by RIA as previously reported [19]. Briefly, one ovary
per point (ten points per treatment) was weighed and homogenized
three times in ethylic alcohol 1:5 (weight of tissue: volume of
alcohol) at room temperature. The extracts were collected and
evaporated in a vacuum oven and saved at 280uC until the RIA
was performed. PGE was quantified by using rabbit antiserum
from Sigma Chemical Co. Sensitivity was 10 pg/tube and cross-
reactivity with other PGs was ,0.1%. Results are expressed as pg/
mg tissue.
Oxidative stress-related parameters
Lipid peroxidation. The amount of malondialdehyde
(MDA) formed from the breakdown of polyunsaturated fatty acids
may be taken as an index of peroxidation reaction. The method
used in the present study was as previously described [27] and
quantifies MDA as the product of lipid peroxidation that reacts
with trichloracetic acid–thiobarbituric acid–HCl 163 (15% (w/v);
0.375% (w/v) and 0.25 M, respectively) yielding a red compound
that absorbs at 535 nm. Homogenates of ovarian pooled tissue
(one ovary per point) were treated with trichloroacetic acid–
thiobarbituric acid–HCl and heated for 15 min in boiling water
bath. After cooling, the flocculent precipitate was removed by
centrifugation at 1000 g for 10 min. The absorbance of samples
was determined at 535 nm. Content of thiobarbituric acid
reactants were expressed as nM MDA formed/mg protein.
Ovarian nitric oxide synthase activity
Nitric oxide synthase (NOS) activity was evaluated as a measure
of NO produced by ovarian tissue. NOS was quantified by
monitoring the production of [L-
14C] citrulline from [L-
14C]
arginine as described previously [19]. Briefly, the frozen ovarian
tissue (one ovary per point and ten points per treatment) was
Figure 3. Prenatal hyperandrogenization and ovarian steroidogenesis. (A) Serum progesterone levels, (B) Serum estradiol levels and (C)
Serum testosterone levels from female offspring of Sprague Dawley rats prenatally injected with 2 mg testosterone (T2 group), 5 mg testosterone
(T5) or vehicle (C). CP: rats from the control group at proestrous stage of the estrous cycle, T2P: rats from the T2 group of treatment at proestrous
stage of the estrous cycle CD: rats from the control group at diestrous stage of the estrous cycle, T2D: rats from the T2 group of treatment at
diestrous stage of the estrous cycle, T5: rats from the T5 group of treatment. a vs b; a vs c and b vs c P,0.0001 by ANOVA test. Each column
represents the mean+SEM from ten different animals, N=20 animals/group.
doi:10.1371/journal.pone.0037658.g003
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boro, NJ, USA) at 0uC in three volumes of 50 mM Hepes, 1 mM
DL-dithiothreitol, 1 mM NADPH and 50 mM L-valine, pH=7.5.
Samples were incubated at 37uC for 15 min with 10 microM
[
14C] arginine (0.3 microCi; 1 Ci=37 GBq). The samples were
centrifuged for 10 min at 1000 g and then applied to 1 ml of
DOWEX AG50W-X8 (Na+ form; Bio-Rad, Hercules, CA, USA)
resin. The radioactivity was measured by liquid scintillation
counting. Results are expressed as pmol/g.min.
Glutathione (GSH) content
The antioxidant metabolite GSH was quantified as previously
described [23]. The reduced form of GSH comprises the bulk of
cellular protein sulphydryl groups. Thus, measurement of acid-
soluble thiol is used to estimate the GSH content in tissue extracts.
Briefly, one ovary per point and ten points for group was
homogenized in homogenization buffer (EDTA (1 mM), KCl
(150 mM), beta Mercoptoethanol (1 mM), Trizma base (20 mM)
and sacarose (500 mM), pH=7.6) and centrifuged at 800 g for
10 minutes at 4uC. Then, supernatants (50 microl/point) were
incubated with 800 microl of 1.5 M Tris buffer (pH 7.4)
containing 50 microl of 5.10
23 M NADPH and 6 IU of GSH
reductase. The reaction involves the enzymatic reduction of the
oxidized form (GSSG) to GSH. When Ellman’s reagent (a
sulphydryl reagent 5, 5-dithiobis-2 nitrobenzoic acid; Sigma and
Co, St Louis, MO, USA) is added to the incubation medium, the
chromophoric product resulting from this reaction develops a
molar absorption at 412 nm that is linear to the first beyond
Figure 4. Prenatal hyperandrogenization and ovarian morphology. (A) A representative ovarian tissue section from rats prenatally injected
with vehicle (Control group),6200. (B) Detail of granulosa (GC), theca cells (TC) and luteinized cells (LC) of ovarian tissue from rats prenatally injected
with vehicle (Control group), 6400. (C) Magnification of conserved oocyte of ovarian tissue from rats in the Control group, 61000. (D) Detail of
conserved oocytes (O) and distribution of granulosa (GC) and theca cells (TC) of ovarian tissue from rats in the Control group, 6400. (E) Detail of
luteinized cells (LC) of ovarian tissue from rats in the Control group, 6400 (F) Magnification of conserved luteinized cells (LC) of ovarian tissue from
rats in the Control group, 61000. (G) A representative ovarian tissue section from rats prenatally injected with 2 mg testosterone (T2 group),
PF=primary follicle, SF=secondary follicle, 6400. (H) A representative atretic oocyte (AO) of ovarian tissue from rats in the T2 group, 6400. (I) A
representative follicular cyst (FC) of ovarian tissue from rats in the T2 group, 6400. (J) Magnification of granulosa (GC) and theca cell (TC) of the
follicular cyst, 61000. (K) Aspect of luteinized cells (LC) of ovarian tissue from rats in the T2 group, 61000. (L) A representative section of ovarian
tissue from rats prenatally injected with 5 mg testosterone (T5 group), AF=antral follicle, 6200. L.C.=luteal cells (M) Follicular cysts (FC) in ovarian
tissue from rats in the T5 group,6400. (N) A detail of altered organization of granulosa (GC) and theca cells (TC) and atretic oocytes (AO) of ovarian
tissue from rats in the T5 group, N=ten ovaries per group.
doi:10.1371/journal.pone.0037658.g004
Figure 5. Percentages of follicles (primary, secondary, antral
and atretic) per group of treatment: control, T2 and T5. Ten
ovaries from each group were fixed in 4% (w/v) paraformaldehyde,
included in paraffin, cut 4 mm per section, placed on gelatin-coated
slides and stained with haematoxylin and eosin.
doi:10.1371/journal.pone.0037658.g005
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expressed as microM GSH/mg protein.
Western blotting
Ovarian tissue were lysed for 20 min at 4uC in lysis buffer
(20 mM Tris–HCl, pH=8.0, 137 mM NaCl, 1% Nonidet P-40
and 10% glycerol) supplemented with protease inhibitors (0.5 mM
PMSF, 0.025 mM N-CBZ-L-phenylalanine chloromethyl ketone,
0.025 mM N9-p-tosyl-lysine chloromethyl ketone and 0.025 mM
L-1-tosylamide-2-phenyl-ethylchloromethyl ketone). The lysate
was centrifuged at 4uC for 10 min at 10,000 g and the pellet
discarded. Protein concentrations in the supernatant were
measured by the Bradford assay (Bio-Rad). After boiling for
5 min, 90 microg of protein from each sample was applied to an
SDS-polyacrylamide gel (10%) and electrophoresis was performed
at 100 Volts for 1.5 h. The separated proteins were transferred
onto nitrocellulose membranes in transfer buffer (20% methanol,
vol/vol; 0.19 M glycine; 0.025 M Tris-Base, pH=8.3) for 1 h at
4uC. Blots were blocked for 1.5 h in TBS (4 mM Tris–HCl,
pH=7.5, 100 mM NaCl) containing bovine serum albumin
(0.1%) at room temperature. Rabbit polyclonal anti-COX2 (Santa
Cruz Biotechnology, Inc., USA) (1:200 overnight), rabbit poly-
clonal anti-StAR (Cayman, Ann Arbor, MI, USA) (1:2000
overnight) or rabbit polyclonal anti-PPAR gamma (Cayman,
Ann Arbor, MI, USA) (1:2500 overnight) were used as primary
antibodies. Rainbow-colored protein mass markers (14.3–
200 kDa, Bio-Rad) were applied to samples to determine the
bands of COX2 (72 kDa), StAR (30 kDa) and PPAR gamma
(67 kDa). Protein bands were visualized by incubating the blots
with biotin-conjugated secondary anti-rabbit IgG (1:5000, 1 h)
followed by streptavidin–peroxidase complex and diaminobenzi-
dine solution. Consistency of protein loading was evaluated by
staining the membranes with Ponceau-S and applying the protein
beta actin (43 kDa) (Sigma Co, USA). The intensities (area6
density) of the individual bands on western blots were quantified
by densitometry (Model GS-700, Imaging Densitometer, Bio-
Rad). The experiment was independently repeated three times.
Results are expressed in arbitrary units.
Protein concentration
Ovarian protein concentration was determined as described by
Bradford [45].
Statistical analysis
Statistical analyses were carried out by using the Instant
program (GraphPad software, San Diego, CA, USA). ANOVA
followed by Newman- Keuls test were used to compare all pairs of
columns. A Bonferroni correction for multiple testing was used to
adjust the threshold for statistical significance to P,0.05.
Results
Prenatal hyperandrogenization and body weight
In order to determine whether prenatal hyperandrogenization
affected fetal development, we determined the body weight at 21
and 60 days of age. We found that hyperandrogenization induces
an adverse intrauterine condition since it diminished the body
weight at 21 days (Fig. 1A, a vs b P,0.01; b vs c P,0.0001; a vs c
P,0.001) as compared with controls. Therefore, the higher dose
of androgen injected caused a significant decrease in body weight
(Fig. 1; T2 vs T5 P,0.0001). This adverse effect of prenatal
hyperandrogenization was compensated when the animals were
60 days of age since no significant differences were found between
groups (Fig. 1B). This mechanism of compensation in the body
weight was clearly manifested by the slope of the growth curve
(Fig. 1C). We also found that the ‘‘compensatory mechanism’’ was
directly related to the dose of testosterone prenatally injected, thus,
the slope of the growth curve (slope of control group=3.717; slope
of T2=3.974; slope of T5=4.160) increased (r=0.99, p=0.0001)
with the dose of testosterone (r=0.66, p=0.0001).
Prenatal hyperandrogenization and glucose homeostasis
The IPGTT used to evaluate homeostasis of glucose. Figure 2
showed that prenatal hyperandrogenization induced increased
levels of circulating glucose. We also found that this effect was
directly related to the dose of testosterone prenatally injected. The
area under the curve (control=165576200; T2=182256150;
T5=196386130 arbitrary units) of glucose concentration clearly
shows that circulating glucose was significantly higher in T5 than
in T2 (P=0.0001, r=0.999).
Glucose homeostasis and body weight
Increased circulating glucose after IPGTT directly correlated
(r=0.99, p=0.0001) with the slope of the growth curve (r=0.66,
p=0.0001).
Prenatal hyperandrogenization and estrous cycle
The uro-genital distance (UGD) determined at 60 days of age
showed that prenatal hyperandrogenization induced defeminiza-
tion since the UGD was significantly increased in T2 and T5
(control=1.3660.15; T2=1.6660.20; T5=1.7560.08 cm; T2
vs control P,0.05; T2 vs T5 P,0.001). With respect to the sexual
cycle, we found that 80/80 (100%) of control rats showed a regular
estrous cycle (4–6 days). In contrast, only 16/80 (20%) of rats from
T2, showed a regular estrous cycle (4–6 days) and T5 rats showed
vaginal opening atresia. Vaginal smears from rats from T2 group
which did not ovulate showed that these rats stayed at diestrous
stage.
Figure 6. Prenatal hyperandrogenization and ovarian inflam-
matory status. Ovarian prostaglandin E content from female offspring
of Sprague Dawley rats prenatally injected with 2 mg testosterone (T2
group), 5 mg testosterone (T5) or vehicle (C). CP: rats from the control
group at proestrous stage of the estrous cycle, T2P: rats from the T2
group of treatment at proestrous stage of the estrous cycle CD: rats
from the control group at diestrous stage of the estrous cycle, T2D: rats
from the T2 group of treatment at diestrous stage of the estrous cycle,
T5: rats from the T5 group of treatment. a vs b P,0.0001 by ANOVA
test. Each column represents the mean+SEM from ten different animals,
N=20 animals/group.
doi:10.1371/journal.pone.0037658.g006
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Steroidogenesis
Since hormonal levels change through the estrous cycle, we
determined both serum progesterone and estradiol levels in two
well differentiated stages of the cycle: proestrus and diestrus. We
chose diestrus because rats from T2 which did not ovulate stayed
at that stage and we chose proestrus because it is the stage of
follicular development which is one of the altered conditions in
PCOS. We found that T2 rats showed increased serum
progesterone levels as compared with controls in both proestrus
and diestrus stages without significant differences between them
(Fig. 3A; a vs b; a vs c and b vs c P,0.0001). Similarly, T5 rats
showed significantly increased serum progesterone levels as
compared to controls. No differences were found between rats
from T2 and T5 (Fig. 3A). As expected, serum levels of estradiol
were lower in control rats in diestrus than in control rats in
proestrus (Fig. 3B; P,0.0001). T2 and T5 showed decreased levels
of serum estradiol as compared with control rats in proestrus
(Fig. 3B; P,0.0001). Serum testosterone levels were increased in
both T2 and T5 as compared with controls (Fig. 3C; P,0.0001).
Rats from T5 showed higher serum testosterone levels than rats
from T2 (Fig. 3C; P,0.0001).
Prenatal hyperandrogenization and ovarian morphology
Ovaries from T2 rats (Fig. 4A–K) and ovaries from T5 rats
(Fig. 4L–O) were smaller than controls (control=5569m gv s
T2=3865 mg; P,0.005; control=5569m gv sT 5=4 2 66 mg,
P,0.005). Ovaries from T2 rats had a larger number of
developing follicles in early stages (primary and secondary follicles:
PF and SF respectively) than controls. These data were quantified
in Fig. 5: b vs a and e vs d; P,0.0001. Ovaries from T2 rats
showed smaller number of antral follicles (Fig. 4G) than ovaries
from control rats (Fig. 4A). These data were quantified in Fig. 5: h
vs g P,0.0001. In contrast with the oocytes from control rats
(Fig. 4C and 4D), oocytes from T2 rats suffered atresia (Fig. 4H)
that it was quantified in Fig. 5: k vs j P,0.0001, and displayed
Figure 7. Prenatal hyperandrogenization and ovarian oxidant-antioxidant balance. (A) Lipid peroxidation, (B) Nitric oxide synthase (NOS)
activity and (C) Content of anti-oxidant gluthatione (GSH) of ovarian tissue from female offspring of Sprague Dawley rats prenatally injected with
2 mg testosterone (T2 group), 5 mg testosterone (T5) or vehicle (C). CP: rats from the control group at proestrous stage of the estrous cycle, T2P: rats
from the T2 group of treatment at proestrous stage of the estrous cycle CD: rats from the control group at diestrous stage of the estrous cycle, T2D:
rats from the T2 group of treatment at diestrous stage of the estrous cycle, T5: rats from the T5 group of treatment. a vs b P,0.0001 by ANOVA test.
Each column represents the mean+SEM from ten different animals, N=20 animals/group.
doi:10.1371/journal.pone.0037658.g007
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of granulosa (GC) and theca (TC) cells (Fig. 4 J) as compared with
control ovaries (Fig. 4B and 4D). Finally, ovaries from T2 rats
displayed abnormal hyper-luteinization (Fig. 4K) characterized by
enhanced pyknotic cells with compacted chromatin (Fig. 4K) as
compared with controls (Fig. 4E and 4F).
Ovaries from T5 rats showed an increased number of atretic
follicles (Fig. 4L: AtF) as compared with controls (Fig. 4A). Since
rats from T5 group showed vaginal opening atresia, we used the
Figure 8. Mechanisms involved in the prenatal hyperandrogenization on ovarian tissue. Western blotting for the expression of the
steroidogenic acute regulatory protein (StAR) in ovarian tissue from rats prenatally injected with vehicle (Control group), 2 mg testosterone (T2
group) or 5 mg testosterone (T5 group). Bands correspond to 30 kDa, (A) A representative Western blot, (B) actin as control protein and (C)
integrated optical density of the bands. Each column represent mean+SEM of ten different animals. a vs b P,0.0001 by ANOVA test. Western blotting
for the expression of the nuclear peroxisome proliferator- activated receptor (PPAR) gamma in ovarian tissue from rats prenatally injected with
vehicle (Control group), 2 mg testosterone (T2 group) or 5 mg testosterone (T5 group). Bands correspond to 67 kDa, (D) A representative Western
blot, (E) actin as control and (F) integrated optical density of the bands. Each column represent mean+SEM of ten different animals. a vs b P,0.0001
by ANOVA test. Western blotting for the expression of cyclooxygenase 2 (COX2) in ovarian tissue from rats prenatally injected with vehicle (Control
group), 2 mg testosterone (T2 group) or 5 mg testosterone (T5 group). Bands correspond to 62 kDa, (G) A representative Western blot, (H) actin as
control and (I) integrated optical density of the bands. Each column represent mean+SEM of ten different animals. a vs b P,0.0001 by ANOVA test,
N=20 animals/group.
doi:10.1371/journal.pone.0037658.g008
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groups. Ovarian morphology of rats from T5 group (Fig. 4L) was
similar to that of rats from the T2 group which did not ovulate and
the two groups stayed in constant diestrus. These data were
quantified in Fig. 5: l vs j P,0.0001, and follicular cysts (three cysts
per ovary) (Fig. 4M: FC: follicular cysts). Oocytes from ovaries
from T5 rats showed atresia (Fig. 4N: AO) and a disorganized
distribution of the surrounding layers of granulosa (GC) and theca
(TC) cells (Fig. 4N). The number of corpus luteum per ovary
between groups did not differ (five corpus luteum/ovary) (data not
shown).
Prenatal hyperandrogenization and ovarian inflammatory
status
To assess whether prenatal hyperandrogenization was able to
induce a pro-inflammatory status in the ovarian tissue, we
determined the PGE content. In order to establish whether the
estrous cycle is able to modify the PGE content, we quantified
PGE from ovarian tissue in proestrus and diestrus (Fig. 6;
P,0.0001). We found that prenatal T2 hyperandrogenization
did not modify PGE content in either stage but that prenatal T5
hyperandrogenization significantly increased PGE content as
compared with controls and T2 rats (Fig. 6; P,0.0001).
Prenatal hyperandrogenization and ovarian oxidant-
antioxidant balance
To determine whether prenatal hyperandrogenization was able
to induce ovarian oxidative stress, lipid peroxidation index, nitric
oxide synthase activity and the antioxidant metabolite; GSH were
evaluated in the ovarian tissue from control, T2 and T5 rats. Since
the content of MDA (the main product which results of lipid
peroxidation) was not modified either in ovarian tissue from T2 or
T5 rats, we inferred no damage in the ovarian membrane (Fig. 7A).
To evaluate the possible accumulation of ROS, we quantified
NOS activity. We found that NOS activity was not modified in T2
or T5 (Fig. 7B). However, the ovarian content of the antioxidant
metabolite GSH was increased in ovarian tissues from T2 and T5
rats (Fig. 7C; P,0.0001).
Mechanisms involved in the prenatal
hyperandrogenization in ovarian tissue
To clarify some of the molecular mechanisms involved in the
altered ovarian steroidogenesis induced by prenatal hyperandro-
genization, the protein expression of the limiting protein that
regulates cholesterol availability, the steroidogenic acute regulato-
ry protein: StAR and the protein expression of the transcriptional
factor PPAR gamma were evaluated by Western blotting (Fig. 8;
P,0.0001).
We found that the protein expression of StAR was increased in
ovarian tissue from T5 rats as compared to both controls and T2
rats (Fig. 8A–C; P,0.0001). We also found that the protein
expression of PPAR gamma was increased in ovarian tissue from
T5 rats as compared to both controls and T2 rats (Fig. 8D–F;
P,0.0001).
In order to determine whether protein expression of COX2, the
limiting enzyme of PG synthesis, was affected by prenatal
hyperandrogenization, we evaluated the protein expression of
COX2. We found that protein expression of COX2 was increased
in ovarian tissue from T5 rats as compared with controls (Fig. 8G–
I; P,0.0001). No significant differences were found between T2
rats and controls (Fig. 8G–I; P,0.0001).
A direct correlation was found between COX2 (T5 vs T2 and
control, P=0.0001, r=0.999) and PPAR gamma (T5 vs T2 and
control, P=0.01; r=0.950).
Discussion
Given the limitations in human studies, murine models are an
important tool to study PCOS. Prenatal hyperandrogenism is
considered as one of the best animal models since, it allows
studying fetal programming [46,47]. In that context, there is
agreement that rats have to be prenatally hyperandrogenized from
days 16 to 19 of gestation (which represent the post- placentation
time and the period in which androgens are responsible for
neuromodulations). There is also agreement that the dose of
androgen has to be similar to the levels observed in male rats,
however, the dose to be injected remains controversial. Wu et al
[16] reported that doses of free testosterone large than 3 mg result
in mortality of fetuses. These authors also found that female
offspring were entirely defeminized. However, Demissie et al [8]
reported that 5 mg testosterone did not induce mortality in fetuses
or offspring but induced defeminization. In the present study, we
used 2 and 5 mg free testosterone to induce prenatal androgeniza-
tion and found that neither doses induced mortality in the fetuses
or the offspring. Moreover, our data are the first demonstration
that alterations induced by prenatal hyperandrogenization depend
on the intrauterine dose which in turn would determine the PCOS
phenotype during the adult life. Offspring prenatally hyperan-
drogenized with 2 mg free testosterone (T2 group) showed
increased levels of serum testosterone, ovarian cysts, and
hyperglycemia but they were able to ovulate, whereas offspring
prenatally hyperandrogenized with 5 mg free (T5 group) showed
increased levels of serum testosterone, hyperglycemia and ovarian
cysts but they stayed in constant diestrus. In fact, it was reflected
by the increased levels of progesterone found in animals from T5
group as compared with controls. These findings are in agreement
with our previous findings [22] and with other authors [48] and
demonstrate that hyperandrogenization induces accelerated follic-
ular growth. As shown by the increased UGD, we also found that
both doses of free testosterone induced defeminization. These
findings are in agreement with previous reports [13] and suggest
that prenatal hyperandrogenism affects the neurosecretory system
of gonadotropin-releasing hormone (GnRH). Taken together our
findings suggest that not only the timing of the in uterus
hyperandrogenization [8,16] but also the concentration of
androgens to which the fetus is subjected would be responsible
for endocrine and metabolic alterations that in turn, would define
the PCOS phenotype. Four phenotypes of PCOS have been
proposed: phenotype 1 or classic defined by anovulation
(AO)+biochemical or clinical hyperandrogenism (HA) and ovarian
cysts (C), phenotype 2 defined by AO+HA, phenotype 3 defined
by HA+ C and phenotype 4 defined by AO+C [4]. However, the
differences between them are poorly studied. Recently, Panidis et
al [49] reported that insulin resistance defines the PCOS
phenotype. In that context, in a prospective study of 1,212 PCOS
patients, they reported that phenotype 1 is associated with more
insulin resistance and more pronounced hyperandrogenism than
the other phenotypes and that phenotypes 2 and 4 are associated
not only with insulin resistance but also with obesity.
Here we found that adult rats prenatally treated with 5 mg free
testosterone showed features corresponding to phenotype 1
whereas those treated with 2 mg free testosterone displayed an
altered condition such as that of phenotype 3. In agreement with
Panidis et al. [49], we found that the more severe alterations of the
two phenotypes correlated with a more negative impact on glucose
Prenatal Hyperandrogenization and PCOS
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analyzing the area under the curve of the glucose homeostasis in
agreement with previous reports [8]. On the other hand, we
demonstrated that the more severe condition of PCOS phenotype
(rats from T5 group which correlated to phenotype 1) showed
lower body weight at 21 days of age than T2 and control rats. In
addition, we found that the lower body weight correlated to the
fastest weight gain as manifested by: i) no significant differences in
the body weight at 60 days of ages and ii) the highest slope of the
growth curve in the lowest body weight. These findings led us to
suggest that a high dose of prenatal testosterone could correlate to
a worse intrauterine environment and with more effective
compensatory mechanism of growth. The relationship between
low birth and precocious pubarche remains controversial and it
appears that ethnic origin is involved [50–57]. However, it is well
accepted that there is an association between low birth and
endocrine-metabolic abnormalities including hyperinsulinemia,
dyslipidemia and ovarian hyperandrogenism [52,54,57]. In
summary, our results demonstrate that the severe PCOS
phenotype induces more endocrine and -metabolic alterations
and consequently a high response related to insulin resistance. In
fact, Barker et al [58] reported that systolic blood pressure during
adult life is inversely related to birth weight. Later studies
confirmed a direct association between low birth and insulin
resistance during adult life [59–61]. All these findings allow
characterizing the syndrome X or small baby syndrome that
postulates that an adverse intrauterine environment results in a
rapid response to glucose metabolism characterized by lower
insulin sensitivity. Here we demonstrated not only that increased
levels of intrauterine testosterone exposure induce severe alter-
ations but also that the mechanisms involved are different. Both
prenatal androgenization (T2 and T5 rats) displayed enhanced
ovarian steroidogenesis characterized by increased levels of
progesterone and testosterone and decreased levels of estradiol.
It is important to point out that enhanced ovarian steroidogenesis
was characterized by an enhanced luteinization as it can be seen in
the morphological studies. These data are in agreement with
previous findings about an accelerated steroidogenic capacity of
theca cells from women with PCOS [62]. With respect to the
mechanism involved, we found that only the higher dose of
testosterone was able to increase the protein expression of StAR,
suggesting another pathway for the lower dose of prenatal
testosterone treatment. A wide range of proteins including
luteinizing hormone receptor, insulin hormone receptor, lipopro-
tein receptor, StAR, P450 side-chain cleavage, 3 beta-hydroxy-
steroid dehydrogenase and cytochrome P450c17 might be over-
expressed in ovaries from PCOS patients [63,64]. Further studies
are being designed to clarify which are the pathways involved in
the ovarian steroidogenesis in PCOS from rats in the T2 group.
We have demonstrated that prenatal hyperandrogenism induces
a pro-inflammatory status in the ovarian tissue mediated by
enhanced ovarian PGE production and COX2 protein expression.
These findings are in agreement with previous studies using other
murine PCOS models [22,23]. Only the higher dose of prenatally
testosterone injected (T5 rats) established an ovarian pro-
inflammatory environment and induced anovulation. Although
PGs are essential for ovulation [17,18], the excess of androgen
enhances ovarian PG production and consequently induces
anovulation [22]. Moreover, anovulatory women with PCOS
display increased production of PGE [21]. We have also previously
demonstrated that the pattern of inflammation correlates with an
enhanced expression of the nuclear transcriptional factor PPAR
gamma. This is in agreement with previous findings about the role
of PPAR gamma in modulating ovarian steroidogenesis during a
condition of acute hyperandrogenism [38]. PPAR gamma not only
regulates the lipid metabolism and lipid profile [65] but also is able
to induce a pro-inflammatory status by enhancing the production
of adipokines [66]. Then, we could infer that the increased protein
expression of PPAR gamma would be indirectly related to the pro-
inflammatory status mediated by PGE. Moreover, it has been
reported that the PPAR system regulates the synthesis of PGs by
modulating COX2, the limiting enzyme of this process [67]. These
findings could explain why we found that the protein expression of
PPAR gamma and COX2 display a similar pattern.
Considering that the excess of androgen induces oxidative stress
[22–26] and that this, in turn, modulates ovarian function
[19,20,23,27] and the fact that nitrogen reactive species (RNOS)
represent more aggressive species than ROS, we also evaluated the
lipid index, the production of NO and the levels of the antioxidant
GSH in the ovarian tissue. We found that neither lipid
peroxidation nor NO synthase activity was modified and GSH
content was increased by prenatal hyperandrogenization. In
agreement with previous findings [68–72], these data could
suggest that a ‘‘controlled response’’, given by the increase of the
anti-oxidant metabolite GSH, could avoid the accumulation of
ROS resulting in a no modification of lipid peroxidation index.
The fact that prenatal hyperandrogenization did not modify the
production of ovarian NO levels could suggest that that condition
did not generate the accumulation of RNOS. However, studies are
designed to clarify these points. In summary, this study demon-
strates that the levels of testosterone prenatally injected are able to
modulate the PCOS phenotype manifested during the adult life.
Both the metabolic and endocrine pathways showed during the
adult life also depend on the levels of testosterone prenatally
injected.
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